1
|
Ricordel C, Chaillot L, Vlachavas EI, Logotheti M, Jouannic A, Desvallees T, Lecuyer G, Aubry M, Kontogianni G, Mastrokalou C, Jouan F, Jarry U, Corre R, Le Guen Y, Guillaudeux T, Lena H, Chatziioannou A, Pedeux R. Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer. Sci Rep 2023; 13:3626. [PMID: 36869231 PMCID: PMC9984363 DOI: 10.1038/s41598-023-30536-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 02/24/2023] [Indexed: 03/05/2023] Open
Abstract
Circulating tumor cells (CTC) have been studied in various solid tumors but clinical utility of CTC in small cell lung cancer (SCLC) remains unclear. The aim of the CTC-CPC study was to develop an EpCAM-independent CTC isolation method allowing isolation of a broader range of living CTC from SCLC and decipher their genomic and biological characteristics. CTC-CPC is a monocentric prospective non-interventional study including treatment-naïve newly diagnosed SCLC. CD56+ CTC were isolated from whole blood samples, at diagnosis and relapse after first-line treatment and submitted to whole-exome-sequencing (WES). Phenotypic study confirms tumor lineage and tumorigenic properties of isolated cells for the 4 patients analyzed with WES. WES of CD56+ CTC and matched tumor biopsy reveal genomic alteration frequently impaired in SCLC. At diagnosis CD56+ CTC were characterized by a high mutation load, a distinct mutational profile and a unique genomic signature, compared to match tumors biopsies. In addition to classical pathways altered in SCLC, we found new biological processes specifically affected in CD56+ CTC at diagnosis. High numeration of CD56+ CTC (> 7/ml) at diagnosis was associated with ES-SCLC. Comparing CD56+ CTC isolated at diagnosis and relapse, we identify differentially altered oncogenic pathways (e.g. DLL3 or MAPK pathway). We report a versatile method of CD56+ CTC detection in SCLC. Numeration of CD56+ CTC at diagnosis is correlated with disease extension. Isolated CD56+ CTC are tumorigenic and show a distinct mutational profile. We report a minimal gene set as a unique signature of CD56+ CTC and identify new affected biological pathways enriched in EpCAM-independent isolated CTC in SCLC.
Collapse
Affiliation(s)
- Charles Ricordel
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France.
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.
| | - L Chaillot
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - E I Vlachavas
- e-NIOS PC, Kallithea-Athens, Greece
- Division of Molecular Genome Analysis (B050), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | | | - A Jouannic
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - T Desvallees
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France
- Unité De Pharmacologie Préclinique, Biotrial Pharmacology, Rennes, France
| | - G Lecuyer
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - M Aubry
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - G Kontogianni
- Centre of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527, Athens, Greece
| | | | - F Jouan
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - U Jarry
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France
- Unité De Pharmacologie Préclinique, Biotrial Pharmacology, Rennes, France
| | - R Corre
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France
| | - Y Le Guen
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France
| | - T Guillaudeux
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France
| | - H Lena
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France
| | - A Chatziioannou
- e-NIOS PC, Kallithea-Athens, Greece
- Centre of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527, Athens, Greece
| | - Rémy Pedeux
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France.
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France.
- CLCC Eugène Marquis, INSERM U1242-OSS, Université Rennes 1, Rue Bataille Flandres Dunkerque, 35042, Rennes, France.
| |
Collapse
|
2
|
Debieuvre D, Auliac J, Bylicki O, Moreau L, Corre R, Pinsolle J, Bizieux Thaminy A, Schneider S, Godbert B, Renault P, Brun P, Bernardi M, Briens E, Lepoulain Doubliez M, Delclaux B, Petit L, Bizec J, Milliet de Faverges G, Al Freijat F, Quieffin J. 132P 20 years of real life nationwide epidemiological data on lung cancer in non-academic French public hospitals: KBP-2020-CPHG compared to 2000 and 2010 studies. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Canouï Poitrine F, Zebachi S, Paillaud E, Chouaid C, Corre R. GERIATRIC AND ONCOLOGICAL PREDICTORS OF SURVIVAL AND CHEMOTHERAPY TOXICITIES IN ELDERLY PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER: AN ANALYSIS OF ESOGIA TRIAL. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31160-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Chouaid C, Levra MG, Corre R, Calvet C, Gaudin AF, Grumberg V, Jolivel R, Jouaneton B, Assié JB, Cotté FE. Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Amrane K, Geier M, Corre R, Léveiller G, Florence G, Lamy R, Bizec J, Goarant E, Robinet G, Ulrike S, Quere G, Bernier C, Descourt R. First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Zalcman G, Mazieres J, Greillier L, Brosseau S, Lantuejoul S, Do P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Planchard D, Ligeza-Poisson C, Amour E, Morin F, Moro-Sibilot D, Scherpereel A. Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz266] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
7
|
Zalcman G, Brosseau S, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Gervais R, Janicot H, Locher C, Langlais A, Parienti J, Morin F, Scherpereel A. MA05.05 Post-Discontinuation Treatments in IFCT-GFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Levra MG, Cotté F, Corre R, Calvet C, Jouaneton B, Jolivel R, Gaudin A, Grumberg V, Assié J, Chouaid C. MA07.06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.551] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Guisier F, Gervais R, Husseini KE, Assié JB, Geier M, Decroisette C, Corre R, Descourt R, Chouaid C, Salaun M, Thiberville L. Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumour response to anti-PD1 treatment. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Saboundji K, Auliac J, Fraboulet G, Andre M, Madelaine J, Quéré G, Masson P, Vergnenegre A, Lamy R, Raymond S, Chiappa A, Hauss P, Fournel P, Corre R, Chouaid C. Tolérance et efficacité de l’osimertinib chez les patients (pts) octogénaires atteints de cancer du poumon non à petites cellules (CPNPC) porteurs d’une mutation T790M de l’Epidermal Growth Factor Receptor (EGFR) pré-traités par inhibiteurs de tyrosine-kinase (ITK) de l’EGFR. Étude Explore T790M, cohorte octogénaire. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Fronteau H, Jestin Le Tallec V, Loisel I, Estivin S, Corre R, Marhuenda F, Grudé F, Déniel-Lagadec D. L’état vaccinal des sujets âgés atteints de cancer recevant une chimiothérapie : rappel des recommandations et zoom sur la région Bretagne. ONCOLOGIE 2018. [DOI: 10.3166/onco-2018-0018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
12
|
Brahmer J, Schenker M, Lee K, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke F, Richardet E, Penrod J, Yuan Y, Nathan F, Bhagavatheeswaran P, De Rosa M, Taylor F, Lawrance R, Reck M. OA05.06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.261] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant E, Bizec J, Bernier C, Quéré G, Couturaud F, Robinet G. MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.383] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Grude F, Corre R, Urban T, Bennouna J, De Chabot G, Chatellier T, Denis F, Descourt R, Douillard JY, Ricordel C, Molinier O, Pinquie F, Robinet G, Travers M, Moiteaux B, Deniel Lagadec D, Marhuenda F. Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medico-economic approach. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Geier M, Descourt R, Corre R, Leveiller G, Le Garff G, Briens E, Lamy R, Goarant E, Bizec J, Bernier C, Quéré G, Gaye E, Montestruc F, Couturaud F, Robinet G. ABCT-IMMUNOBZH : évaluation de l’efficacité du nivolumab dans la vraie vie chez 259 patients porteurs d’un cancer bronchique non à petites cellules de stade avancé. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2018.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Duvergé L, Bondiau P, Bellec J, Corre R, Ricordel C, De Latour B, Doyen J, De Crevoisier R, Chajon E, Castelli J. EP-1386: Impact of the stereotactic irradiation schedule for non-small-cell lung carcinoma stage I. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31695-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Auliac J, Guisier F, Robinet G, Oliviero G, Thomas P, Baize N, Chouaid C, Corre R. Tolérance et efficacité en monde réel des inhibiteurs tyrosine-kinase (TKI) de l’EGFR chez les patients octogénaires atteints de cancer du poumon non à petites cellules (CPNPC) porteurs d’une mutation activatrice de l’EGFR. Étude OCTOMUT GFPC 07-15. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Geier M, Descourt R, Quéré G, Corre R, Leveiller G, Lamy R, Goarant E, Bizec J, Bernier C, Couturaud F, Robinet G. P2.07-030 Real Life Second-Line Nivolumab in Advanced Non-Small-Cell-Lung Cancer: A French Observational Multicenter Study of 259 Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.089] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Corre R, Gervais R, Tassy L, Guisier F, Lamy R, Fraboulet G, Greillier L, Doubre H, chouaid C, Auliac J. Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Zalcman G, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Thiberville L, Urban T, Planchard D, Ligeza-Poisson C, Amour E, Morin F, Moro-Sibilot D, Scherpereel A. Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.074] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Gauvain C, Lena H, Corre R, Ricordel C, Vinas F, Chouaid C. Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non à petites cellules. ONCOLOGIE 2016. [DOI: 10.1007/s10269-016-2633-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
|
23
|
Zalcman G, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy M, Creveuil C, Parienti J, Morin F, Scherpereel A. Essai randomisé de phase 3 comparant le triplet bévacizumab à 15mg/kg associé au cisplatine et au pémétrexed (CP) au doublet de CP dans les mésothéliomes pleuraux malins (MPM) : résultats de l’essai IFCT-GFPC-0701 MAPS. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
24
|
Auliac JB, Fournier C, Audigier Valette C, Perol M, Bizieux A, Vinas F, Decroisette Phan van Ho C, Bota Ouchlif S, Corre R, Le Garff G, Fournel P, Baize N, Lamy R, Vergnenegre A, Arpin D, Marin B, Chouaid C, Gervais R. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study. Target Oncol 2015; 11:167-74. [DOI: 10.1007/s11523-015-0387-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
25
|
De Latour B, Guihaire J, Kerjouan M, Corre R, Rouze S, Lentz PA, Meunier C, Roisne A, Lena H, Flecher E, Verhoye JP. Place du robot en chirurgie thoracique : expérience rennaise initiale et revue de la littérature. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Colliaux J, Castelli J, Chajon E, Bellec J, Henry O, Le Prisé E, Léna H, Corre R, De Crevoisier R. EP-1168 Tumor regression on CBCT predicts the risk of recurrence and death in locally advanced non-small cell lung cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41160-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Auliac J, Chouaid C, Greillier L, Monnet I, Le Caer H, Falchero L, Corre R, Descourt R, Bota S, Berard H, Schott R, Bizieux A, Fournel P, Labrunie A, Marin B, Vergnenegre A. Corrigendum to “Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study” [Lung Cancer 85 (2014) 415–419]. Lung Cancer 2015. [DOI: 10.1016/j.lungcan.2014.12.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Tiercin-Labalette M, Lespagnol A, Denis M, Le Gac G, Zalcman G, Bout J, Bizec JL, Marc M, Richard N, Lena H, Corre R. Octomut, étude observationnelle rétrospective multicentrique épidémiologique des patients de 80ans et plus avec un CBNPC muté EGFR et traités par EGFR-TKI. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Gervais R, Molinier O, Chouaid C, Barlesi F, Denis F, Berard H, Corre R, Dansin E, Lecaer H, Moro-Sibilot D, Rebattu P, Burki F, Khayat D, Le Moulec S, Pérol M, Pouessel D, Robinet G, Nanda S, Depenbrock H, Socinski MA, Thatcher N. SQUIRE : étude multicentrique randomisée de phase III, en ouvert, évaluant gemcitabine-cisplatine (GC) plus necitumumab versus GC en première ligne de traitement du CBNPC épidermoïde (épi) de stade IV. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
30
|
Le Caer H, Chouaid C, Corre R, Locher C, Raynaud C, Berard H, Auliac J, Crequit J, Decroisette C, Borget I. Impact of a comprehensive geriatric assessment on management strategies in elderly patients with advanced no small cell lung cancer (NSCLC): A polled analysis of two phase 2 prospective study of the GFPC group. J Geriatr Oncol 2014. [DOI: 10.1016/j.jgo.2014.09.163] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Bigay-Gamé L, Bota S, Greillier L, Monnet I, Madroszyk A, Corre R, Mastroianni B, Falchero L, Chouaid C, Audigier-Valette C, Baize N, Daniel C, Fraboulet G, Gossot D, Raynaud C, Mazières J, Colineaux H, Lepage B, Robinet G. Lung Cancer in Patients Under 40 Years: a Prospective Observational Multicenter Study (Groupe Français De Pneumo-Cancérologie (Gfpc) 1001 Study). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu357.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Corre R, Chouaid C, Greillier L, Caer HL, Valette CA, Baize N, Berard H, Falchero L, Descourt R, Dansin E, Vergnenegre A, Bigay-Gamé L, Schott R, Garff GL, Treut JL, Sureda BM, Daures J, Plassot C, Lena H. Quality of Life Analysis of Esogia-Gfpc-Gecp Trial- a Phase Iii, Randomized, Multicenter Study Comparing in Elderly Patients (≥70 Years) with Stage Iv Nsclc a Treatment Allocation Based on Ps and Age with an Experimental Strategy According to a Comprehensive Geriatric Assessment (Cga). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Auliac J, Fournier C, Valette CA, Perol M, Bizieux A, Monnet I, De van Ho CCP, Ouchlif SB, Corre R, Garff GL, Fournel P, Baize N, Lamy R, Vergnenegre A, Arpin D, Marin B, Greillier L, Gervais R. Retrospective Multicenter Study in Non Small Cell Lung Cancer (Nsclc) Patients with Epidermal Growth Factor Receptor (Egfr) Activating Mutation Treated First-Line Tyrosine Kinase Inhibitor (Tki): Evaluation of Progression According to Recist, Therapeutic Approach and Its Effect. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Auliac JB, Chouaid C, Greillier L, Monnet I, Le Caer H, Falchero L, Corre R, Descourt R, Bota S, Berard H, Schott R, Bizieux A, Fournel P, Labrunie A, Marin B, Vergnenegre A. Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. Lung Cancer 2014; 85:415-9. [PMID: 25082565 DOI: 10.1016/j.lungcan.2014.07.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Revised: 07/07/2014] [Accepted: 07/10/2014] [Indexed: 11/18/2022]
Abstract
BACKGROUND Concomitant administration of erlotinib with standard chemotherapy does not appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but preliminary studies suggest that sequential administration might be effective. OBJECTIVE To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. METHODS In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). The primary endpoint was the progression-free survival rate at 15 weeks (PFS 15). Secondary endpoints included PFS, overall survival (OS), the overall response rate (ORR) and tolerability. Based on a Simon optimal two-stage design, the ED strategy was rejected if the primary endpoint was below 33/66 patients at the end of the two Simon stages. RESULTS 147 patients were randomized (median age: 60±8 years, PS 0/1/2: 44/83/20 patients; males: 78%). The ED strategy was rejected, with only 18 of 73 patients achieving PFS15 in arm ED at the end of stage 2 and 17 of 74 patients in arm D. In arms ED and D, respectively, median PFS was 2.2 and 2.5 months and median OS was 6.5 and 8.3 months. CONCLUSION Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status.
Collapse
Affiliation(s)
- J B Auliac
- Department of Pneumology, Quesnay Hospital, Mantes La Jolie, France.
| | - C Chouaid
- Department of Pneumology, Saint Antoine Hospital, Paris, France
| | | | - I Monnet
- Service de pneumologie, CHI, Creteil, France
| | - H Le Caer
- CH de Draguignan, Draguignan, France
| | - L Falchero
- CH Villefranche Sur Saone, Villefranche-sur-Saone, France
| | - R Corre
- Pneumology, CHU Pontchaillou, Rennes, France
| | | | - S Bota
- Hôpital Charles Nicolle, Rouen, France
| | | | - R Schott
- Centre Paul Strauss, Strasbourg, France
| | - A Bizieux
- CHD La Roche Sur Yon, La Roche Sur Yon, France
| | - P Fournel
- Institut de Cancérologie de la Loire, Saint Priest En Jarez, France
| | | | - B Marin
- CEBIMER, CHU limoges, Limoges, France
| | | |
Collapse
|
35
|
De Latour B, Corre R, Guihaire J, Kerjouan M, Rouze S, Meunier C, Sellin M, Lena H, Verhoye JP. L’expérience rennaise des lobectomies pulmonaires par vidéothoracoscopie (VATS) sans écartement des côtes : à propos de 46 patients. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Chajon E, Bellec J, Castelli J, Kerjouan M, Corre R, Lena H, Molina S, Le Prisé E, De Crevoisier R. EP-1156: Low esophageal toxicity during simultaneous modulated accelerated radiotherapy (SMART) in locally advanced NSCLC. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31274-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Héry G, Corre R, Leveiller G, Dansin E, Migaud I, Sohier L, Morel H, Jouneau S, Briens E. Intérêt du drain pleural tunnélisé (DPT) dans les pleurésies néoplasiques récidivantes : étude rétrospective sur 129 cas. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2013.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
38
|
Héry G, Jouneau S, Corre R, Briens E, Leveiller G, Migaud I, Morel H, Dansin E. Drain pleural tunnélisé dans les pleurésies métastatiques : étude rétrospective sur 129 cas. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Bylicki O, Segura C, Chouaid C, Lavolé A, Barlesi F, Gervais R, Westeel V, Crequit J, Corre R, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Linard P, Perol D, Perol M. Efficacité du pemetrexed en 2e ligne dans les CBNPC avancé après un intervalle libre ou un traitement de maintenance par gemcitabine ou erlotinib dans l’étude IFCT-GFPC 05-02. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
LeCaer H, Greillier L, Corre R, Jullian H, Crequit J, Falchero L, Dujon C, Berard H, Vergnenegre A, Chouaid C. A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). Lung Cancer 2012; 77:97-103. [DOI: 10.1016/j.lungcan.2012.02.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Revised: 02/03/2012] [Accepted: 02/05/2012] [Indexed: 12/27/2022]
|
41
|
LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C. A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). Br J Cancer 2011; 105:1123-30. [PMID: 21934690 PMCID: PMC3208485 DOI: 10.1038/bjc.2011.331] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs erlotinib followed by DG after progression (arm B) in fit elderly patients with advanced non small-cell lung cancer (NSCLC). METHODS Elderly chemotherapy-naive patients with stage IIIB/IV NSCLC were selected after a comprehensive geriatric assessment (socioeconomic, cognitive, depression, ADL and IADL assessments). The primary endpoint was the time to second progression (TTP2). Overall survival (OS), the time to first progression (TTP1) and safety were secondary endpoints. RESULTS Between July 2006 and November 2008, 22 centres enrolled 100 patients. TTP2 was 7.5 and 5.8 months in arm A and arm B, respectively; TTP1 was 4.7 and 2.7 months; and the median OS time was 9.4 and 7.1 months; the respective 1-year survival rates were 36.2 and 31.4%. There was no major unexpected toxicity. CONCLUSION These results suggest that weekly DG, followed by erlotinib, is a promising treatment for fit elderly patients with NSCLC; the efficacy of the reverse sequence was insufficient to recommend it for EGFR-non-selected patients.
Collapse
Affiliation(s)
- H LeCaer
- Services de Pneumologie, CH Route Montferrat 83300, Draguignan, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Corre R, Chouaid C, Barlesi F, Le Caer H, Dansin E, Vergnenegre A, Fournel P. Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an “optimized” strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps219] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, Garcia Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Di Seri M, Garrido Lopez P, Insa A, De Marinis F, Corre R, Carreras M, Carcereny E, Taron M, Paz-Ares LG. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7503] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Le Caer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C. A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)*0504. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Denis MG, Theoleyre S, Chaplais C, Gourdet H, Caulet-Maugendre S, Le Ho H, Corre R, Lena H, Sagan C, Bennouna J. Efficient detection of EGFR alterations in lung adenocarcinomas. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10556] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Jullian H, Greillier L, Chouaid C, Corre R, Crequit J, Falchero L, Dujon C, Berard H, Auliac JB, Le Caer H. A multicenter phase II randomized study of gemcitabine (G) weekly followed by erlotinib (E) after progression versus E followed by G after progression in advanced non-small cell lung cancer (NSCLC) in vulnerable elderly patients selected with a comprehensive geriatric assessment (CGA) (GFPC*0505). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Corre R, Vergnenègre A, Le Caer H, Fournel P. P69 Study ESOGIA-GFPC 08–02 – elderly selection on geriatric index assessment. Crit Rev Oncol Hematol 2009. [DOI: 10.1016/s1040-8428(09)70107-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
48
|
Le Caer H, Barlesi F, Corre R, Jullian H, Balas D, Chouaid C. P66 A multicenter phase II randomized study of docetaxel/gemcitabine weekly followed by erlotinib after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA) (gfpc*0504): preliminary results. Crit Rev Oncol Hematol 2009. [DOI: 10.1016/s1040-8428(09)70104-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
49
|
Abstract
The occurrence of pain during the course of bronchial carcinoma is nearly inescapable and often constitutes the main symptom for patients and those close to them. While pain control is held to be a priority of care in cancerology in the future, this goal is not always reached due to insufficient implementation of recommendations, however widely accessible. Our aim is to present the different aspects of pain treatment through the details of both pharmacological and nonpharmacological means.
Collapse
Affiliation(s)
- V Morel
- Equipe Mobile d'Accompagnement et de Soins Palliatifs, Pôle Soins de Support, Hôpital Hôtel-Dieu, CHU de Rennes, 2 Rue de l'Hôtel-Dieu, CS 26419, 35064 Rennes Cedex, France.
| | | | | | | | | |
Collapse
|
50
|
Vergnenegre A, Corre R, Barlési F, Bérard H, Vernejoux J, Le Caer H, Fournel P, Delhoume J, Arpin D, Thomas P, Tillon J. A randomized phase II trial of early change of a chemotherapeutic doublet compared to four cycles of chemotherapy in advanced non-small cell lung cancer (NSCLC): The 03–01 Groupe Francais de Pneumo-Cancerologie (GFPC) study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7631 Background: The optimal strategy in advanced NSCLC with stable disease is not well known. There is no published study assessing an early change of chemotherapeutic drugs in these patients. This study was designed to evaluate the efficacy and safety of early modification of chemotherapy doublets in patients with advanced non small cell lung cancer with stable disease (SD). Methods: Patients with stage IV NSCLC and measurable disease were included in a randomized phase II trial comparing for patients with stable disease after 2 cycles of a platin (P)-gemcitabine doublet (P d1: 75 mg/m2, gemcitabine 1 250 mg/m2 d1, d8 every three weeks) two subsequent cycles of this doublet (arm A) to a switch to another doublet (arm B): paclitaxel 100 mg/m2 d1, d8, d15, gemcitabine 1 250 mg/m2 d1, d8, every four weeks. Results: Between October 2003 and august 2006, 228 patients (pts) were enrolled (187 males, 41 females), median age 57 y (30–70). Evaluation (EVA) 1 showed 11.8% not assessable patients (NA), 19.3% with objective responses (OR), 25.9% with progressive diseases. 98 patients (43%) had stable diseases. 87 patients were randomized in the study. 48.3% with PS0, 51.7% with PS1 and a majority of adenocarcinoma (62.1%). 41.4% had only one metastatic site. There were no differences between the two groups. Efficacy at eva 2 is depicted above. Overall survival (OS) was similar between the two arms: 9.8 months (m) [7.0 - 14.2] for arm A, 9.2 m [7.4 - 10.5] for arm B. TTP was 5.4 m in arm A and 5.7 in arm B. There were 1 grade III/IV haematological toxicities in arm A (1.2%) and 2 in arm B (2.4%). There were 4 grade III/IV non haematological toxicities in arm A (4.8%) and 6 in arm B (7.3%). Conclusions: The switch between the two regimen is feasible without any major toxicities. Despite higher response rate in favour of the switch strategy, OS and TTP are similar between the two arms. No significant financial relationships to disclose. [Table: see text]
Collapse
Affiliation(s)
- A. Vergnenegre
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - R. Corre
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - F. Barlési
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - H. Bérard
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - J. Vernejoux
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - H. Le Caer
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - P. Fournel
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - J. Delhoume
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - D. Arpin
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - P. Thomas
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| | - J. Tillon
- Service De Pneumologie, Limoges, France; Hôpital Pontchailloux, Rennes, France; Hôpital Ste Marguerite, Marseille, France; Hôpital d’Instruction des Armées Sainte Anne, Toulon, France; Hôpital du Haut Lévêque, Pessac, France; Centre Hospitalier, Draguignan, France; Institut de Cancérologie de la Loire, St Priest en Jarez, France; Centre Hospitalier, Périgueux, France; Hôpital de la Croix Rousse, Lyon, France; Centre Hospitalier Intercommunal des Alpes du Sud, Gap, France; Centre Hospitalier Universitaire
| |
Collapse
|